Diabetes mellitus and coronary atherosclerosis
Abstract
Diabetic patients have the excess risk of developing atherosclerotic coronary artery disease (CAD), which is the most common cause of death in diabetes. The major contributor to the increased CAD risk in patients with type 2 diabetes is dyslipidemia. The multicomponent pathogenesis of accelerated coronary atherosclerosis in diabetes remains incompletely understood. At present there is not convincing evidence of intensive glucose control benefit for prevention cardiovascular complications of diabetes. Low-density lipoprotein cholesterol is recognized as the primary target of the treatment of dyslipidemia in diabetic patients and statins are the drugs of choice for lowering low-density lipoprotein cholesterol. In patients with diabetes and hypertension the main determinant of the cardiovascular benefits of antihypertensive drugs is the blood pressure level achieved under treatment, but nevertheless pharmacologic therapy should include either an angiotensin-converting enzyme inhibitors or an angiotensin II receptor antagonist.
About the Authors
V. I. Volkov
Academy of Medical Sciences of Ukraine
Ukraine
Ukraine
State Institution "L. T. Malaya Institute of Therapy
61039
avenue. Postysheva, 2a
Kharkiv
S. A. Serik
Academy of Medical Sciences of Ukraine
Ukraine
Ukraine
State Institution "L. T. Malaya Institute of Therapy
61039
avenue. Postysheva, 2a
Kharkiv
References
1. Shaw J. E., Sicree R. A., Zimmet P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030 // Diabetes Res. Clin. Pract. 2010. Vol. 87, N 1. P. 4–14.
2. Hurst R. T., Lee R. W. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management // Ann. Intern. Med. 2003. Vol. 139, N 10. P. 824–834.
3. Kannel W. B., McGee D. L. Diabetes and cardiovascular risk factors: the Framingham study // Circulation. 1979. Vol. 59, N 1. P. 8–13.
4. Fuller J. H., Shipley M. J., Rose G. et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study // Br. Med. J. (Clin. Res. Ed.). 1983. Vol. 287, N 6396. P. 867–870.
5. Stamler J., Vaccaro O., Neaton J., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial // Diabetes Care. 1993. Vol. 16, N 2. P. 434–444.
6. Fox C. S., Coady S., Sorlie P. D. et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study // Circulation. 2007. Vol. 115, N 12. P. 1544–1550.
7. Haffner S. M., Lehto S., Ronnema T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction// N. Engl. J. Med. 1998. Vol. 339. P. 229–234.
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults // JAMA. 2001. Vol. 285, N 19. P. 2486–2497.
9. Bulugahapitiya U., Siyambalapitiya S., Sithole J., Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis // Diabet. Med. 2009. Vol. 26, N 2. P. 142–148.
10. Emerging Risk Factors Collaboration, Sarwar N., Gao P., Seshasai S. R. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies // Lancet. 2010. Vol. 375, N 9733. P. 2215–2222.
11. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies // BMJ. 2006. Vol. 332, N 7533. P. 73–78.
12. Kjaergaard S. C., Hansen H. H., Fog L., et al. In-hospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era // Scand. Cardiovasc. J. 1999. Vol. 33, N 3. P. 166–170.
13. Malmberg K., Yusuf S., Gerstein H. C. et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry // Circulation. 2000. Vol. 102, N 9. P. 1014–1019.
14. Miettinen H., Lehto S., Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction The FINMONICA Myocardial Infarction Register Study Group// Diabetes Care. 1998. Vol. 21, N 1. P. 69–75.
15. Herlitz J., Karlson B. W., Lindqvist J., Sjolin M. Rate and mode of death during five years of follow-up among patients with acute chest pain with and with-out a history of diabetes mellitus // Diabet. Med. 1998. Vol. 15, N 4. P. 308–314.
16. Donahoe S. M., Stewart G. C., McCabe C. H. et al. Diabetes and mortality following acute coronary syndromes // JAMA. 2007. Vol. 298, N 7. P. 765–775.
17. Turner R. C., Millns H., Neil H. A. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) // BMJ. 1998. Vol. 316, N 7134. P. 823–828.
18. Despres J. P., Lamarche B., Mauriege P. et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease // N. Engl. J. Med. 1996. Vol. 334, N 15. P. 952–957.
19. Lehto S., Ronnemaa T., Pyorala K., Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes // Diabetologia. 2000. Vol. 43, N 2. P. 148–155.
20. Soinio M., Marniemi J., Laakso M. et al. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. A 7-year follow-up study // Diabetes Care. 2006. Vol. 29, N 2. P. 329–333.
21. Ledru F., Ducimetiere P., Battaglia S. et al. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study // J. Am. Coll. Cardiol. 2001. Vol. 37, N 6. P. 1543–1550.
22. Natali A., Vichi S., Landi P. et al. Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome? // Diabetologia. 2000. Vol. 43, N 5. P. 632–641.
23. Cariou B., Bonnevie L., Mayaudon H. et al. Angiographic characteristics of coronary artery disease in diabetic patients compared with matched non-diabetic subjects // Diabetes Nutr. Metab. 2000. Vol. 13, N 3. P. 134–1341.
24. Werner G. S., Richartz B. M., Heinke S. et al. Impaired acute collateral recruitment as a possible mechanism for increased cardiac adverse events in patients with diabetes mellitus // Eur. Heart J. 2003. Vol. 24, N 12. P. 1134–1142.
25. Nicholls S. J., Tuzcu E. M., Kalidindi S. et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials // J. Am. Coll. Cardiol. 2008. Vol. 52, N 4. P. 255–262.
26. Moreno P. R., Murcia A. M., Palacios I. et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus // Circulation. 2000. Vol. 102, N 18. P. 2180–2184.
27. Biondi-Zoccai G. G., Abbate A., Liuzzo G. et al. Atherothrombosis, inflammation, and diabetes // J. Am. Coll. Cardiol. 2003. Vol. 41, N 7. P. 1071–1077.
28. Orchard T. J., Costacou T., Kretowski A., Nesto R. W. Type 1 diabetes and coronary artery disease // Diabetes Care. 2006. Vol. 29, N 11. P. 2528–2538.
29. Steiner G. Atherosclerosis in type 2 diabetes: a role for fibrate therapy?// Diab. Vasc. Dis. Res. 2007. Vol. 4, N 4. P. 368–374.
30. D’Souza A., Hussain M., Howarth F. C. et al. Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart // Mol. Cell. Biochem. 2009. Vol. 331, N 1-2. P. 89–116.
31. Reusch J. E., Draznin B. B. Atherosclerosis in diabetes and insulin resistance // Diabetes Obes. Metab. 2007. Vol. 9, N 4. P. 455–463.
32. Virella G., Lopes-Virella M. F. Atherogenesis and the humoral immune response to modified lipoproteins // Atherosclerosis. 2008. Vol. 200, N 2. P. 239–246.
33. Серик С. А. Липопротеинсодержащие иммунные комплексы у больных ишемической болезнью сердца с сахарным диабетом 2 типа / С. А. Серик, В. И. Волков, Т. А. Ченчик // Укр. терапевт. журн. – 2008. – № 1. – С. 19–23.
34. Eckel R. H., Wassef M., Chait A. et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes // Circulation. 2002. Vol. 105, N 18. P. e138–e143.
35. Stern M. P. Diabetes and cardiovascular disease. The «common soil» hypothesis // Diabetes. 1995. Vol. 44, N 4. P. 369–374.
36. Ceriello A., Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24, N 5. P. 816–823.
37. Lotufo P. A. The «common soil» theory: coronary disease, diabetes and inflammation // Sao Paulo Med. J. 2005. Vol. 123, N 5. P. 207–208.
38. Alexandraki K., Piperi C., Kalofoutis C. et al. Inflammatory process in type 2 diabetes: The role of cytokines // Ann. N. Y. Acad. Sci. 2006. N 1084. P. 89–117.
39. Koshiyama H., Honjo S., Hamamoto Y. et al. Drugs share antidiabetic and antiatherosclerotic actions through «the common soil» // Med. Hypotheses. 2006. Vol. 66, N 3. P. 473–475.
40. Scrivo R., Vasile M., Bartosiewicz I., Valesini G. Inflammation as «common soil» of the multifactorial diseases // Autoimmun. Rev. 2011. Vol. 10, N 7. P. 369–374.
41. King P., Peacock I., Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes// Br. J. Clin. Pharmacol. 1999. Vol. 48, N 5. P. 643–648.
42. Stettler C., Allemann S., Jüni P. et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials // Am. Heart J. 2006. Vol. 152, N 1. P. 27–38.
43. Gerstein H. C., Miller M. E., Byington R. P. et al. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. 2008. Vol. 358, N 24. P. 2545–2559.
44. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. 2009. Vol. 360, N 2. P. 129–139.
45. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. 2008. Vol. 358, N 24. P. 2560–2572.
46. Mannucci E., Monami M., Lamanna C. et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials // Nutr. Metab. Cardiovasc. Dis. 2009. Vol. 19, N 9. P. 604–612.
47. Ray K. K., Seshasai S. R., Wijesuriya S. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials // Lancet. 2009. Vol. 373, N 9677. P. 1765–1772.
48. Marso S. P., Kennedy K. F., House J. A., McGuire D. K. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis // Diab. Vasc. Dis. Res. 2010. Vol. 7, N 2. P. 119–130.
49. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials // BMJ. 2011. Jul 26; 343: d4169. doi: 10.1136/bmj.d4169
50. O’Keefe J. H., Abuannadi M., Lavie C. J., Bell D. S. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus // Mayo Clin. Proc. 2011. Vol. 86, N 2. P. 128–138.
51. Taskinen M. R. Diabetic dyslipidaemia: from basic research to clinical practice // Diabetologia. 2003. Vol. 46, N 6. P. 733–749.
52. Solano M. P., Goldberg R. B. Management of dyslipidemia in diabetes// Cardiol. Rev. 2006. Vol. 14, N 3. P. 125–135.
53. Rosengren A., Welin L., Tsipogianni A., Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study // BMJ. 1989. Vol. 299, N 6708. P. 1127–1131.
54. Jacobs M. J., Kleisli T., Pio J. R. et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States // Diabetes Res. Clin. Pract. 2005. Vol. 70, N 3. P. 263–269.
55. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A. L., De Backer G. et al. ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees, Bax J., Vahanian A., Auricchio A. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. 2011. Vol. 32, № 14. P. 1769–1818.
56. Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials // BMJ. 2006. Vol. 332, N 7550. P. 1115–1124.
57. Pyorala K., Pedersen T. R., Kjekshus J. et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) // Diabetes Care. 1997. Vol. 20, N 4. P. 614–620.
58. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study // Lancet. 1994. Vol. 344, N 8934. P. 1383–1389.
59. Haffner S. M., Alexander C. M., Cook T. J. et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis in the Scandinavian Simvastatin Survival Study // Arch. Intern. Med. 1999. Vol. 159, N 22. P. 2661–2667.
60. Goldberg R. B., Mellies M. J., Sacks F. M. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol And Recurrent Events (CARE) trial // Circulation. 1998. Vol. 98, N 23. P. 2513–2519.
61. Keech A., Colquhoun D., Best J. et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Results from the LIPID trial // Diabetes Care. 2003. Vol. 26, N 10. P. 2713–2721.
62. Serruys P. W., de Feyter P., Macaya C. et al. Lescol Intervention Prevention Study (LIPS) Investigators: Fluvastatin for the prevention of cardiac events following successful first percutaneous coronary intervention. A randomised controlled trial // JAMA. 2002. Vol. 287, N 24. P. 3215–3222.
63. Sever P. S., Dahlof B., Poulter N. R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial // Lancet. 2003. Vol. 361, N 9364. P. 1149–1158.
64. Sever P. S., Dahlof B., Poulter N. R. et al. Reduction in cardiovascular eventswith atorvastatinin 2,532 patients with type 2 diabetes // Diabetes Care. 2005. Vol. 28, N 5. P. 1151–1157.
65. Shepherd J., Cobbe S. M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group // N. Engl. J. Med. 1995. Vol. 333, N 20. P. 1301–1307.
66. Downs J. R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force / Texas Coronary Atherosclerosis Prevention Study // JAMA. 1998. Vol. 279, N 20. P. 1615–1622.
67. The ALLHAT Officers and Coordinators for the ALL-HAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to prevet Heart Attack Trial (ALLHAT-LLT) // JAMA. 2002. Vol. 288, N 23. P. 2998–3007.
68. Heart Protection Study Collaborative Group. MCR / BHF Heart Protection Study of cholesterol-lower-ing with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial // Lancet. 2003. Vol. 361, N 9374. P. 2005–2016.
69. Kjekshus J., Apetrei E., Barrios V. et al. For the CORONA Group. Rosuvastatin in Older Patients with Systolic Heart Failure // N. Engl. J. Med. 2007. Vol. 357, N 22. P. 2248–2261.
70. Coulhoun H. M., Betteridge D. J., Durrrington P. N. et al. The Collaborative Atorvastatin Diabetes Study (CARDS) investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial // Lancet. 2004. Vol. 364, N 9435. P. 685–696.
71. Knopp R. H., d’Emden M., Smilde J. G., Pocock S. J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) // Diabetes Care. 2006. Vol. 29, N 7. P. 1478–1485.
72. Gazi I. F., Mikhailidis D. P. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp // Diabetes Care. 2006. Vol. 29, N 11. P. 2561.
73. Knopp R. H. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): Response to Gazi and Mikhailidis // Diabetes Care. 2006. Vol. 29, N 11. P. 2561–2562.
74. LaRosa J. C., Grundy S. M., Waters D. D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease // N. Engl. J. Med. 2005. Vol. 352, N 14. P. 1425–1435.
75. Shepherd J., Barter P., Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study // Diabetes Care. 2006. Vol. 29, N 6. P. 1220–1226.
76. Ahmed S., Cannon C. P., Murphy S. A., Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial // Eur. Heart J. 2006. Vol. 27, N 19. P. 2323–2329.
77. Ito M. K., Talbert R. L., Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction // Pharmacotherapy. 2006. Vol. 26, N 7, Pt. 2. P. 85S–97S.
78. Almuti K., Rimawi R., Spevack D. et al. Effects of statins beyond lipid lowering: potential for clinical benefits // Int. J. Cardiol. 2006. Vol. 109, N 1. P. 7–15.
79. Zhou Q., Liao J. K. Pleiotropic effects of statins. – Basic research and clinical perspectives // Circ. J. 2010. Vol. 74, N 5. P. 818–826.
80. Ludwig S., Shen G. X. Statins for diabetic cardiovascular complications // Curr. Vasc. Pharmacol. 2006. Vol. 4, N 3. P. 245–251.
81. Blaha V., Andrys C., Smahelova A. et al. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover // Pharmacol. Res. 2006. Vol. 54, N 6. P. 421–428.
82. Koh K. K., Quon M. J., Han S. H. et al. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes // Atherosclerosis. 2007. Vol. 194, N 1. P. 230–237.
83. Ceriello A. Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes // Curr. Opin. Lipidol. 2006. Vol. 17, N 5. P. 510–518.
84. Tawfik H. E., El-Remessy A. B., Matragoon S. et al. Simvastatin improves diabetes-induced coronary endothelial dysfunction // J. Pharmacol. Exp. Ther. 2006. Vol. 319, N 1. P. 386–395.
85. Tekin G., Tekin A., Canatar T. et al. Simvastatin improves the attenuated heart rate recovery of type 2 diabetics // Pharmacol. Res. 2006. Vol. 54, N 6. P. 442–446.
86. Save V., Patil N., Moulik N., Rajadhyaksha G. Effect of atorvastatin on type 2 diabetic dyslipidemia // J. Cardiovasc. Pharmacol. Ther. 2006. Vol. 11, N 4. P. 262–270.
87. Hogue J. C., Lamarche B., Tremblay A. J. et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus // Metabolism. 2008. Vol. 57, N 3. P. 380–386.
88. Usharani P., Mateen A. A., Naidu M. U. et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study // Drugs R. D. 2008. Vol. 9, N 4. P. 243–250.
89. Kater A. L., Batista M. C., Ferreira S. R. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe// Metabolism. 2010. Vol. 59, N 6. P. 921–926.
90. Abe M., Toyohara T., Ishii A. et al. The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides // Drug Metab. Pharmacokinet. 2010. Vol. 25, N 3. P. 274–282.
91. Kawagoe Y., Hattori Y., Nakano A. et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients // Endocr. J. 2011. Vol. 58, N 3. P. 171–175.
92. Cumaoрlu A., Ozansoy G., Irat A. M. et al. Effect of long term, non cholesterol lowering dose of fluvastatin treatment on oxidative stress in brain and peripheral tissues of streptozotocin-diabetic rats // Eur. J. Pharmacol. 2011. Vol. 654, N 1. P. 80–85.
93. Feng B., Xu L., Wang H. et al. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products // Biochim. Biophys. Acta. 2011. Vol. 1812, N 9. P. 1130–1137.
94. Muhlestein J. B., May H. T., Jensen J. R. et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study // J. Am. Coll. Cardiol. 2006. Vol. 48, N 2. P. 396–401.
95. Blanco-Colio L. M., Martin-Ventura J. L., de Teresa E. et al. ACTFAST investigators Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27, N 1. P. 168–174.
96. Blanco-Colio L. M., Martin-Ventura J. L., de Teresa E. et al. ACTFAST investigators. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration // Am. Heart J. 2007. Vol. 153, N 5. P. 881–888.
97. Blanco-Colio L. M., Martín-Ventura J. L., Gómez-Guerrero C. et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk // Eur. J. Pharmacol. 2008. Vol. 586, N 1-3. P. 259–265.
98. Lam H. C., Chu C. H., Wei M. C. et al. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia // Exp. Biol. Med. (Maywood). 2006. Vol. 231, N 6. P. 1010–1015.
99. Isley W. L., Park Y., Harris W. S. The effect of high dose simvastatin on, platelet size in patients with, type 2 diabetes mellitus // Platelets. 2006. Vol. 17, N 5. P. 292–295.
100. Beishuizen E. D., Tamsma J. T., Jukema J. W. et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease // Diabetes Care. 2005. Vol. 28, N 7. P. 1668–1674.
101. Takebayashi K., Matsumoto S., Wakabayashi S. et al. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia // Metabolism. 2005. Vol. 54, N 9. P. 1225–1229.
102. Howes L. G. The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients // Diabetes Obes. Metab. 2006. Vol. 8, N 1. P. 8–14.
103. Sattar N., Preiss D., Murray H. M. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials // Lancet. 2010. Vol. 375, N 9716. P. 735–742.
104. Preiss D., Seshasai S. R., Welsh P. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis // JAMA. 2011. Vol. 305, N 24. P. 2556–2564.
105. Rosenson R. S. Cholesterol lowering in diabetes: new evidence supports aggressive LDL-C targets // Post-grad. Med. 2005. Vol. 117, N 4. P. 17–27.
106. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney P. M., Blackwell L., Collins R. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis // Lancet. 2008. Vol. 371, N 9607. P. 117–125.
107. Fruchart J. C., Sacks F., Hermans M. P. et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia // Am. J. Cardiol. 2008. Vol. 102, N 10, Suppl. P. 1K–34K.
108. Miller M., Cannon C. P., Murphy S. A. et al. PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial // J. Am. Coll. Cardiol. 2008. Vol. 51, N 7. P. 724–730.
109. Faergeman O., Holme I., Fayyad R. et al. Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease // Am. J. Cardiol. 2009. Vol. 104, N 4. P. 459–463.
110. Mikhailidis D. P., Sibbring G. C., Ballantyne C. M. et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy // Curr. Med. Res. Opin. 2007. Vol. 23, N 8. P. 2009–2026.
111. Goldberg R. B., Guyton J. R., Mazzone T. et al. Ezetimibe / simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study // Mayo Clin. Proc. 2006. Vol. 81, N 12. P. 1579–1588.
112. Fleg J. L., Mete M., Howard B. V. et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial // J. Am. Coll. Cardiol. 2008. Vol. 52, N 25. P. 2198–2205.
113. Rubins H. B., Robins S. J., Collins D. et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VAHIT) // Arch. Intern. Med. 2002. Vol. 162, N 22. P. 2597–2604.
114. Manninen V., Elo M. O., Frick M. H. et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study // JAMA. 1988. Vol. 260, N 5. P. 641–651.
115. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study // Circulation. 2000. Vol. 102, N 1. P. 21–27.
116. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study // Lancet. 2001. Vol. 357, N 9260. P. 905–910.
117. Keech A., Simes R. J., Barter P. et al. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial // Lancet. 2005. Vol. 366, N 9500. P. 1849–1861.
118. Scott R., O’Brien R., Fulcher G. et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome // Diabetes Care. 2009. Vol. 32, N 3. P. 493–498.
119. ACCORD Study Group. Ginsberg H. N., Elam M. B., Lovato L. C. et al. Effects of combination lipid therapy in type 2 diabetes mellitus // N. Engl. J. Med. 2010. Vol. 362, N 17. P. 1563–1574.
120. Chapman M. J., Redfern J. S., McGovern M. E., Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk // Pharmacol. Ther. 2010. Vol. 126, N 3. P. 314–345.
121. Canner P. L., Furberg C. D., Terrin M. L., McGovern M. E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) // Am. J. Cardiol. 2005. Vol. 95, N 2. P. 254–257.
122. Goldberg R. B., Jacobson T. A. Effects of niacin on glucose control in patients with dyslipidemia // Mayo Clin. Proc. 2008. Vol. 83, N 4. P. 470–478.
123. Brown B. G., Zhao X. Q., Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease // N. Engl. J. Med. 2001. Vol. 345, N 22. P. 1583–1592.
124. Taylor A. J., Lee H. J., Sullenberger L. E. The effect of 24 mo of combination statin and extended-release niacin on carotid intima media thickness: ARBITER 3 // Curr. Med. Res. Opin. 2006. Vol. 22, N 11. P. 2243–2250.
125. AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL / high triglyc-erides: impact on Global Health outcomes (AIM-HIGH) trial // Am. Heart. J. 2011. Vol. 161, N 3. P. 538–543.
126. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE// http://www.clinicaltrials.gov/ct2/show/NCT00461630
127. Mita T., Watada H., Ogihara T. et al. Eicosapentaenoic acid reduces the progression of carotid intimamedia thickness in patients with type 2 diabetes // Atherosclerosis. 2007. Vol. 191, N 1. P. 162–167.
128. Rydén L., Standl E., Bartnik M. et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) // Eur. Heart J. 2007. Vol. 28, N 1. P. 88–136.
129. American Diabetes Association. Standards of medical care in diabetes – 2011 // Diabetes Care. 2011. Vol. 34, Suppl. 1. P. S11–S61.
130. Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal // J. Hypertens. 2009. Vol. 27, N 5. P. 923–934.
131. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. 2009. Vol. 27, N 11. P. 2121–2158.
132. Cushman W. C., Evans G. W., Byington R. P. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus // N. Engl. J. Med. 2010. Vol. 362, N 17. P. 1575–1585.
133. Cooper-DeHoff R. M., Gong Y., Handberg E. M. et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease // JAMA. 2010. Vol. 304, N 1. P. 61–68.
134. Reboldi G., Gentile G., Angeli F. et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients // J. Hypertens. 2011. Vol. 29, N 7. P. 1253–1269.
135. Turnbull F., Neal B., Algert C. et al. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. 2005. Vol. 165, N 12. P. 1410–1419.
136. Chobanian A. V., Bakris G. L., Black H. R. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure // Hypertension. 2003. Vol. 42, N 6. P. 1206–1252.
137. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators // Lancet. 2000. Vol. 355, N 9200. P. 253–259.
138. Pfeffer M. A., Swedberg K., Granger C. B. et al. CHARM Investigators and Committees.Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme // Lancet. 2003. Vol. 362, N 9386. P. 759–766.
139. Reboldi G., Gentile G., Angeli F., Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials // Vasc. Health. Risk. Manag. 2009. Vol. 5, N 1. P. 411–427.
140. Weber M. A., Bakris G. L., Jamerson K. et al. Cardiovascular events during differing hypertension therapies in patients with diabetes // J. Am. Coll. Cardiol. 2010. Vol. 56, N 1. P. 77–85.
Review
For citations:
Volkov V.I., Serik S.A. Diabetes mellitus and coronary atherosclerosis. Ateroscleroz. 2011;7(2):5-22. (In Russ.)
Views:
584
Email this article 